JP2022516318A5 - - Google Patents

Info

Publication number
JP2022516318A5
JP2022516318A5 JP2021538996A JP2021538996A JP2022516318A5 JP 2022516318 A5 JP2022516318 A5 JP 2022516318A5 JP 2021538996 A JP2021538996 A JP 2021538996A JP 2021538996 A JP2021538996 A JP 2021538996A JP 2022516318 A5 JP2022516318 A5 JP 2022516318A5
Authority
JP
Japan
Prior art keywords
item
mir
lnp
copies
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012237 external-priority patent/WO2020142725A1/en
Publication of JP2022516318A publication Critical patent/JP2022516318A/ja
Publication of JP2022516318A5 publication Critical patent/JP2022516318A5/ja
Priority to JP2024143254A priority Critical patent/JP2024167285A/ja
Pending legal-status Critical Current

Links

JP2021538996A 2019-01-04 2020-01-03 カプセル化ポリヌクレオチド及び使用方法 Pending JP2022516318A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024143254A JP2024167285A (ja) 2019-01-04 2024-08-23 カプセル化ポリヌクレオチド及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962788504P 2019-01-04 2019-01-04
US62/788,504 2019-01-04
US201962895135P 2019-09-03 2019-09-03
US62/895,135 2019-09-03
PCT/US2020/012237 WO2020142725A1 (en) 2019-01-04 2020-01-03 Encapsulated rna polynucleotides and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024143254A Division JP2024167285A (ja) 2019-01-04 2024-08-23 カプセル化ポリヌクレオチド及び使用方法

Publications (2)

Publication Number Publication Date
JP2022516318A JP2022516318A (ja) 2022-02-25
JP2022516318A5 true JP2022516318A5 (cg-RX-API-DMAC7.html) 2023-01-19

Family

ID=71406664

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538996A Pending JP2022516318A (ja) 2019-01-04 2020-01-03 カプセル化ポリヌクレオチド及び使用方法
JP2024143254A Pending JP2024167285A (ja) 2019-01-04 2024-08-23 カプセル化ポリヌクレオチド及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024143254A Pending JP2024167285A (ja) 2019-01-04 2024-08-23 カプセル化ポリヌクレオチド及び使用方法

Country Status (13)

Country Link
US (1) US20220117902A1 (cg-RX-API-DMAC7.html)
EP (1) EP3906039A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022516318A (cg-RX-API-DMAC7.html)
KR (1) KR20210113260A (cg-RX-API-DMAC7.html)
CN (1) CN113453699A (cg-RX-API-DMAC7.html)
AU (1) AU2020204989A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021013155A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124524A1 (cg-RX-API-DMAC7.html)
IL (1) IL284433A (cg-RX-API-DMAC7.html)
MX (1) MX2021008146A (cg-RX-API-DMAC7.html)
SG (1) SG11202107282VA (cg-RX-API-DMAC7.html)
TW (1) TW202043480A (cg-RX-API-DMAC7.html)
WO (1) WO2020142725A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
WO2021016194A1 (en) 2019-07-19 2021-01-28 Racaniello Vincent R Second generation seneca valley virus oncolytic therapy: compositions and methods thereof
JP2022543610A (ja) * 2019-08-05 2022-10-13 ヴァイロジン バイオテック カナダ リミテッド 遺伝子改変エンテロウイルスベクター
US20230062603A1 (en) * 2020-01-07 2023-03-02 Translate Bio Ma, Inc. Formulations for delivery of oligonucleotides to lung cells
EP4271389A4 (en) * 2020-12-29 2026-04-08 Rejuvenation Tech Inc COMPOSITIONS AND METHODS FOR ADMINISTRATING RNA
CA3204244A1 (en) * 2021-01-06 2022-07-14 Lorena Lerner Encapsulated rna polynucleotides and methods of use
WO2022159508A1 (en) * 2021-01-19 2022-07-28 Seneca Therapeutics, Inc. Armed seneca valley virus oncolytic therapy compositions and methods thereof
WO2022182792A1 (en) * 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20220347112A1 (en) * 2021-03-31 2022-11-03 Rejuvenation Technologies Inc. Compositions and methods for delivery of rna
EP4387657A4 (en) * 2021-08-17 2025-05-21 Monash University Lipid nanoparticle formulations
CN118251212A (zh) * 2021-09-30 2024-06-25 日油株式会社 用于将核酸递送至淋巴管内皮细胞的脂质纳米颗粒
US12622979B2 (en) 2021-09-30 2026-05-12 Nof Corporation Lipid nanoparticle used for delivering nucleic acid to brain tissue
CN113980915B (zh) * 2021-11-04 2023-07-07 江苏省人民医院(南京医科大学第一附属医院) 一种新型的表达cxcl10的复制型溶瘤腺病毒和应用
FR3129833B1 (fr) 2021-12-03 2024-09-06 Univ Claude Bernard Lyon Nanoparticules pour la liberation d’acides nucleiques
WO2023165583A1 (zh) * 2022-03-04 2023-09-07 益杰立科(上海)生物科技有限公司 靶向眼部细胞的递送系统和方法
US20260077037A1 (en) * 2022-07-04 2026-03-19 Bharat Biotech International Limited Cationic lipid based composition, formulation and use for nucleic acid vaccine delivery and preparation thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用
US20260165980A1 (en) * 2022-10-21 2026-06-18 Georgia Tech Research Corporation Lymphatic endothelial cell-specific lipid nanoparticle and uses thereof
EP4704855A1 (en) * 2023-04-26 2026-03-11 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
KR20250042873A (ko) 2023-09-20 2025-03-28 한국과학기술연구원 종양 표적 리간드를 포함하는 지질나노입자, 이의 제조방법 및 이를 포함하는 약학 조성물
WO2025196641A1 (ru) * 2024-03-19 2025-09-25 Биоплатформ Гмбх Гибридные частицы, способ их получения и применение
WO2025230906A1 (en) * 2024-04-29 2025-11-06 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638318B2 (en) * 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
CN102166218A (zh) * 2005-01-17 2011-08-31 溶瘤病毒有限公司 治疗肿瘤的方法和组合物
DK2002003T3 (en) * 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
EP2125032A4 (en) * 2007-02-20 2011-02-23 Mayo Foundation CANCER TREATMENT WITH VIRAL NUCLEIC ACID
TW201021853A (en) * 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable cationic lipids for nucleic acids delivery systems
WO2013073480A1 (ja) * 2011-11-18 2013-05-23 日油株式会社 細胞内動態を改善したカチオン性脂質
CA2874490C (en) * 2012-05-23 2021-11-16 The Ohio State University Tertiary quaternary amine-based cationic lipid nanoparticle compositions and methods of making and methods of using the same
WO2014171526A1 (ja) * 2013-04-17 2014-10-23 国立大学法人九州大学 遺伝子改変コクサッキーウイルス
WO2016118724A1 (en) * 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
AU2017212713B2 (en) * 2016-01-27 2023-01-19 Oncorus, Inc. Oncolytic viral vectors and uses thereof
EP3478321A4 (en) * 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
JP7306653B2 (ja) * 2017-03-17 2023-07-11 国立大学法人千葉大学 構造強化されたS-TuDを用いた新規がん治療法
US12037608B2 (en) * 2017-04-19 2024-07-16 The University Of Tokyo Genetically engineered coxsackievirus, and pharmaceutical composition
EP3630807B1 (en) * 2017-05-25 2025-08-13 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
RU2020106730A (ru) * 2017-07-14 2021-08-16 Онкорус, Инк. Инкапсулированные полинуклеотиды и способы их применения

Similar Documents

Publication Publication Date Title
JP2024503623A5 (cg-RX-API-DMAC7.html)
Liu et al. mRNA-based cancer therapeutics
Qin et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases
Han et al. Nanomaterials for therapeutic RNA delivery
US11713336B2 (en) Peptides and nanoparticles for intracellular delivery of molecules
Feng et al. RNA therapeutics-research and clinical advancements
Tyagi et al. Exploiting nanotechnology for the development of microRNA-based cancer therapeutics
JP2020530778A5 (cg-RX-API-DMAC7.html)
JP2022507269A5 (cg-RX-API-DMAC7.html)
Cai et al. Synthetic circRNA therapeutics: innovations, strategies, and future horizons
JP2021522248A (ja) 粒子状製剤用の凍結保護剤
CN113453699A (zh) 包封的rna多核苷酸及使用方法
JP2023528300A5 (cg-RX-API-DMAC7.html)
RU2020106730A (ru) Инкапсулированные полинуклеотиды и способы их применения
Son et al. Development of mRNA vaccines/therapeutics and their delivery system
Zwolsman et al. Engineering lipid nanoparticles for mRNA immunotherapy
Abaza et al. Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
Tian et al. DNA Nanomaterials‐Based Platforms for Cancer Immunotherapy
CN117159495A (zh) 脂质纳米颗粒及其应用
CN118556131A (zh) 用于蛋白质表达的mRNA及其模板
Begum et al. Advances in targeted gene delivery
Yang et al. Advancing cancer treatment: in vivo delivery of therapeutic small noncoding RNAs
CN114517211A (zh) 一种基于脂质体递送mRNA的免疫细胞培养及特异性负载激活方法
Zhang et al. Cellular functions and biomedical applications of circular RNAs: Cellular functions and biomedical applications of circular RNAs
Wang et al. Targeted gene delivery systems for T-cell engineering